Roche’s Tecentriq showed promising results in reducing the risk of death and disease recurrence by 41% and 36%, respectively, in muscle-invasive bladder cancer patients compared to a placebo. The study, IMvigor011, utilized a ctDNA-guided approach, presenting data at ESMO Congress 2025. These results may revolutionize post-surgery treatment for MIBC patients, potentially sparing some from unnecessary therapy. Personalized treatment options could improve outcomes for the 150,000 individuals diagnosed with MIBC annually. The study involved 761 participants and utilized Natera’s Signatera ctDNA test for detection of MRD. Tecentriq is a monoclonal antibody designed to target PD-L1. Tecentriq has been shown to reduce the risk of death by 41% and the risk of disease recurrence or death by 36% compared to a placebo in the IMvigor011 study, the first global phase III study to implement a ctDNA-guided approach to post-surgery treatment in muscle-invasive bladder cancer. These findings will be presented at the ESMO Congress 2025, shedding light on treatment options and outcomes for nonmetastatic muscle-invasive bladder cancer. This research is a significant advancement in the perioperative treatment of bladder cancer, addressing challenges for public health and clinical practice.

Read more at Tecentriq shows promising results in reducing the risk of death and disease recurrence in bladder cancer patients.
– GlobeNewswire: Roche’s Tecentriq showed significant overall and